Process Chemistry in Antiviral Research.
This article reviews antiviral therapies that have been approved for human use during the last decade, with a focus on the process chemistry that enabled access to these important drugs. In particular, process chemistry highlights from the practical syntheses of the HCV drugs sofosbuvir (Gilead), grazoprevir (Merck), and elbasvir (Merck), the HIV therapy darunavir (Tibotec) and the influenza treatment peramivir (BioCryst) are presented.
Department of Process Chemistry, Merck and Co., Inc., PO Box 2000, Rahway, NJ, 07065, USA. yongli_zhong@merck.com.
Yong-Li
http://orcid.org/0000-0003-0069-9010
YL
Zhong
Department of Process Chemistry, Merck and Co., Inc., PO Box 2000, Rahway, NJ, 07065, USA.
Nobuyoshi
N
Yasuda
Department of Process Chemistry, Merck and Co., Inc., PO Box 2000, Rahway, NJ, 07065, USA.
Hongming
H
Li
Department of Process Chemistry, Merck and Co., Inc., PO Box 2000, Rahway, NJ, 07065, USA.
Mark
M
McLaughlin
Department of Process Chemistry, Merck and Co., Inc., PO Box 2000, Rahway, NJ, 07065, USA.
David
D
Tschaen
D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D055808:Drug Discovery; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*
D000998:Antiviral Agents
Antivirals; Asymmetric synthesis; Darunavir; Elbasvir; Grazoprevir; HCV; HIV; Influenza; Peramivir; Practical synthesis; Process chemistry; Sofosbuvir